NCT06963021 - NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

Major Depressive Disorder

Interventions

DRUG

NBI-1065845

NBI-1065845 tablets

DRUG

Placebo

Matching placebo tablets

Trial Locations (9)

RECRUITING

Neurocrine Clinical Site, New York

RECRUITING

Neurocrine Clincial Site, New York

RECRUITING

Neurocrine Clinical Site, Cedarhurst

RECRUITING

Neurocrine Clinical Site, Gaithersburg

RECRUITING

Neurocrine Clinical Site, Maitland

RECRUITING

Neurocrine Clinical Site, Tampa

RECRUITING

Neurocrine Clinical Site, Los Angeles

RECRUITING

Neurocrine Clinical Site, Cromwell

RECRUITING

Neurocrine Clinical Site, Farmington